{"id":854892,"date":"2023-01-25T06:00:14","date_gmt":"2023-01-25T05:00:14","guid":{"rendered":"https:\/\/bebeez.it\/non-categorizzato\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/"},"modified":"2023-01-25T06:00:14","modified_gmt":"2023-01-25T05:00:14","slug":"verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero","status":"publish","type":"post","link":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/","title":{"rendered":"Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer"},"content":{"rendered":"Combination of Avutometinib with Defactinib Declared as Go Forward Treatment Regimen in Low-Grade Serous Ovarian Cancer (LGSOC) Program\n\n\nBlinded Independently Confirmed Response Rates in Both KRAS Mutant and KRAS Wild-Type Tumors and Favorable Safety and Tolerability Profile Supports Continued Development in All Recurrent LGSOC\n\n\nCompany Intends to File for Accelerated Approval; Timing Based on Mature Data from RAMP 201 Study and Finalization of Confirmatory Study Plans\n\n\nManagement to Host Conference Call Today at 6:00 PM ET\n\nBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announces positive interim data from Part A of the ongoing R
Abbonati<\/a> o Accedi<\/a> per leggere il resto di questo contenuto.<\/div><\/div>","protected":false},"excerpt":{"rendered":"

Combination of Avutometinib with Defactinib Declared as Go Forward Treatment Regimen in Low-Grade Serous Ovarian Cancer (LGSOC) Program Blinded Independently Confirmed Response Rates in Both KRAS Mutant and KRAS Wild-Type Tumors and Favorable Safety and Tolerability Profile Supports Continued Development in All Recurrent LGSOC Company Intends to File for Accelerated Approval; Timing Based on Mature […]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49625],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-854892","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-north-america"],"acf":[],"yoast_head":"\nVerastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer - BeBeez\" \/>\n<meta property=\"og:description\" content=\"Combination of Avutometinib with Defactinib Declared as Go Forward Treatment Regimen in Low-Grade Serous Ovarian Cancer (LGSOC) Program Blinded Independently Confirmed Response Rates in Both KRAS Mutant and KRAS Wild-Type Tumors and Favorable Safety and Tolerability Profile Supports Continued Development in All Recurrent LGSOC Company Intends to File for Accelerated Approval; Timing Based on Mature […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-25T05:00:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer\",\"datePublished\":\"2023-01-25T05:00:14+00:00\",\"dateModified\":\"2023-01-25T05:00:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/\"},\"wordCount\":2396,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in North America\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/\",\"name\":\"Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2023-01-25T05:00:14+00:00\",\"dateModified\":\"2023-01-25T05:00:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/","og_locale":"en_US","og_type":"article","og_title":"Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer - BeBeez","og_description":"Combination of Avutometinib with Defactinib Declared as Go Forward Treatment Regimen in Low-Grade Serous Ovarian Cancer (LGSOC) Program Blinded Independently Confirmed Response Rates in Both KRAS Mutant and KRAS Wild-Type Tumors and Favorable Safety and Tolerability Profile Supports Continued Development in All Recurrent LGSOC Company Intends to File for Accelerated Approval; Timing Based on Mature […]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/","og_site_name":"BeBeez","article_published_time":"2023-01-25T05:00:14+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/"},"author":{"name":"","@id":""},"headline":"Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer","datePublished":"2023-01-25T05:00:14+00:00","dateModified":"2023-01-25T05:00:14+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/"},"wordCount":2396,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in North America"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/","name":"Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2023-01-25T05:00:14+00:00","dateModified":"2023-01-25T05:00:14+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/verastem-oncology-announces-positive-data-and-regulatory-update-from-planned-interim-analysis-of-registration-directed-phase-2-ramp-201-trial-of-avutometinib-and-defactinib-in-recurrent-low-grade-sero\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/854892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=854892"}],"version-history":[{"count":0,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/854892\/revisions"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=854892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=854892"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=854892"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=854892"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=854892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}